Needham raised the firm’s price target on SI-Bone (SIBN) to $20 from $19 and keeps a Buy rating on the shares as part of a broader research note on MedTech/Diagnostics sector. Following the recent pre-announcements and management commentary, the firm is updating its forecasts on select names while also rolling forward its valuation framework to 2026 estimates, the analyst tells investors in a research note.